$4.29
+0.04 (+0.94%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where MOLN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
10 interventional
Held by 1 tracked-famous manager (CITADEL ADVISORS LLC) · FINRA short interest 1.8 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid TumorsNCT07278479To assess incidence and severity of safety events following administration of [212Pb]Pb-DOTAM-MAM279Open-label · Treatment | Phase 1/2 | Recruiting | Drug: [212Pb]Pb-MP0712 · Other: [203Pb]Pb-MP0712 | Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Small Cell Lung Cancer (SCLC), Gastroenteropancreatic NEC (GEP NEC), NEC of the Bladder, Other DLL3 Expressing epNEC | 138 | Sep 2028 | ≤ 773 d | 2026-05-22 |
| Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic SyndromeNCT05673057Phase 1 dose escalation: Recommended Phase 2 Dose Regimen and/or Maximum Tolerated Dose RegimenNon-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1, MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm A, MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclax, MP0533 with Obinutuzumab pretreatment, MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B relapsed/refractory AML, MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B in treatment naïve patients | Leukemia, Myeloid, Acute, Newly Diagnosed | 249 | 2026-05-29actual | — | 2026-06-09 |
| First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid TumorsNCT05098405Type, incidence and severity of AEs and serious adverse events (SAEs)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: After completion of the dose-escalation part of the study, the safety profile of MP0317 in monotherapy is considered adequately characterized in the dose-escalation part of the study. | Drug: MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q3w regimen), MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q1w regimen) | Advanced Malignant Solid Tumor | 46 | 2024-01-19actual | — | 2025-01-30 |
| Study to Investigate the Safety, Blood Levels and Activity of MP0310 in Patients With Advanced Solid TumorsNCT04049903Incidence of Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: MP0310 | Advanced Solid Tumor | 38 | 2022-06-27actual | — | 2022-12-22 |
| Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)NCT04870164Vital Signs: Blood Pressure Systolic and Diastolic (mmHg)Randomized · Quadruple-masked · Other | Phase 1 | Terminatedsponsor's stated reason: Due to hypersensitivity observed in 3 subjects, although no stopping rules were met, the Sponsor decided to halt recruitment for further investigation. After analysis of PK, i.m. administration was not required, and recruitment stopped. | Drug: Ensovibep, Placebo | COVID-19 | 53 | 2022-01-06actual | — | 2022-03-18 |
| First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274 in Cancer Patients With HER2-positive Solid TumorsNCT03084926Incidence and severity of adverse eventsOpen-label · Treatment | Phase 1 | Completed | Drug: MP0274 | Neoplasms | 22 | 2021-12-13actual | — | 2022-01-10 |
| Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 PatientsNCT04834856SARS-CoV-2 viral loadNon-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: ensovibep | Covid19 | 12 | 2021-08-20actual | — | 2021-09-08 |
| A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple MyelomaNCT03136653Part 1: Overall Response Rate (ORR)Open-label · Treatment | Phase 1/2 | Completed | Biological: MP0250 plus BOR+DEX | Multiple Myeloma in Relapse | 33 | 2020-10-12actual | — | 2021-08-25 |
| MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLCNCT03418532Estimate the objective response rate (ORR)Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor's decision | Combination product: MP0250 DARPin® drug candidate, Osimertinib | EGFR-mutated NSCLC (Disorder) | 8 | 2019-08-30actual | — | 2023-03-23 |
| First-in-human Study to Investigate the Safety, Tolerability and Blood Levels of the Test Drug MP0250 in Cancer PatientsNCT02194426Proportion of patients with dose limiting toxicitiesOpen-label · Treatment | Phase 1/2 | Completed | Drug: MP0250 | Neoplasms | 58 | 2018-02-20actual | — | 2019-08-07 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19